Siltuximab(CNTO-328) is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.

In xenograft mouse models, Siltuximab, when administered through intraperitoneal injection at a dosage of 10 mg/kg three times per week, inhibits the growth of lung cancer cells[1]. Furthermore, in a xenograft model, the growth of MCF-7 tumors is inhibited by Siltuximab with intraperitoneal injections at a dose of 20 mg/kg twice per week for 6 weeks[3].

Human

Immobilized Human IL-6 Protein (His) at 2 μg/mL (30 μL/well) can bind Siltuximab. The EC50 is 58.73 ng/mL.

Monoclonal

Unconjugated